Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on May 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). WuXi Biologics selected as non-exclusive commercial supplier for veligrotug drug substance and product, contingent on approval.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- WuXi Biologics selected as non-exclusive commercial supplier for veligrotug drug substance and product, contingent on approval
- Five-year initial manufacturing term with automatic five-year renewals, requiring 24 months’ non-renewal notice
- Binding, non-cancellable forecast commitments create future supply obligations for Viridian
- Volume-based pricing fixed through December 31, 2026, with potential annual adjustments thereafter
- Alternate manufacturers remain permitted, preserving sourcing flexibility and reducing single-supplier dependence
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.